Title of the pitching session:
Meet the Venture Leaders Biotech 2026
Pitching session summary
Meet the 2026 Swiss National Startup Team in Biotech before they embark on their exclusive roadshow to Boston!
Join us for an exciting evening as 10 of Switzerland’s most promising biotech startups take the stage to pitch their breakthrough innovations. This is a unique opportunity to discover the companies shaping the future of biotech and connect with founders, investors, and ecosystem leaders.
The Venture Leaders Biotech program is organized by Venturelab and supported by the University of Basel, EPF Lausanne, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, and VISCHER.
Date, time and room information
Monday, May 4, 17:45 - 18:30, room Singapore
Moderation
| Name | Position | Institution |
|---|---|---|
| Jordi Montserrat | Co-founder and Managing Partner | Venturelab |
| Maurice Stäheli | Project Manager | Venturelab |
Pitching companies
| Company name | Pitcher | Title of presentation | Link to company website |
|---|---|---|---|
| Baio Labs | Ilia Igashov | The biotech startup uses generative AI to design novel small molecule drugs for specific therapeutic targets in seconds, replacing slow, costly traditional screening. | https://baiolabs.com/ |
| Baxiva | Timothy Keys | Baxiva develops glycoconjugate vaccines to prevent serious bacterial infections, starting with ExPEC, using scalable nanoparticle conjugation. | https://www.baxiva.com/ |
| Biodelphis Therapeutics | Aaron Petruzzella | The biotech startup creates peptide-based drugs that selectively inhibit disease-causing proteases and target specific cells, avoiding toxicity. | https://biodelphis.com/ |
| Bioscibex | Chloé Albietz | Bioscibex produces single-use bioreactors that simplify antibody manufacturing by combining multiple cell expansion steps into one safe, efficient process. | https://www.bioscibex.com |
| GlioCART | Patrice Zeis | GlioCART develops CAR-T therapies for glioblastoma that directly attack tumors while reprogramming immune cells to enhance the anti-tumor response. | https://gliocart.ch/ |
| Immitra Bio | Amir Taheri | The biotech startup builds an in-vivo gene editing platform that allows fast, off-the-shelf treatments without chemotherapy or lengthy ex-vivo processes. | https://immitrabio.com/ |
| NanoZymeX | Boris Sevarika | NanoZymeX delivers therapeutic enzymes into cells using lipid nanoparticles, improving efficacy and reducing immune side effects for rare diseases. | https://www.nanozymex.com/ |
| Translation-X | Özgür Genç | The biotech startup Translation-X develops brain-penetrant inhibitors to correct RNA translation dysregulation in autism subtypes, targeting specific molecular pathways. | https://www.trx-therapeutics.com/ |
| UNOMR | Til Schlotter | UNOMR provides single-molecule protein analysis with nanopore sensors to study modifications like glycosylation for therapy and medical applications. | https://unomr.com/ |
| Visienco | Edwige Guinet | The biotech startup automates organoid sorting and analysis with AI, improving throughput, reproducibility, and scalability for research and clinical use. | https://www.visienco.ch/ |
